The following is a summary of the Champions Oncology, Inc. (CSBR) Q1 2025 Earnings Call Transcript:

Financial Performance:

• Champions Oncology reported a Q1 2025 revenue of $14.1 million, a 12% increase from Q1 2024.

• GAAP income from operations for Q1 2025 was $1.3 million, a significant improvement from a loss of $2.6 million in the prior year.

• Adjusted EBITDA was $2 million for Q1 2025, compared to an adjusted loss of $1.7 million in Q1 2024.

• Operational efficiencies resulted in a gross margin improvement to 50%, up from 40% last year.

Business Progress:

• Implemented operational efficiencies that reduced costs and improved revenue conversion.

• Renewed emphasis on strategic reductions in R&D expenditure while maintaining core business investments.

• Continued engagement with investors to support growth and operational improvements.

Opportunities:

• The funding environment is showing signs of improvement, providing a potential for increased customer R&D budgets.

• Passage of the BIOSECURE Act could block certain competitors, potentially opening up market share opportunities for Champions Oncology.

Risks:

• The business still faces some challenges and volatility in financial results is expected moving forward.

• External pressures on the biotech sector and customer R&D budget constraints continue to pose risks.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.